Sign in
Not yet recruitingPhase 3

Rivaroxaban plus aspirin to prevent blood clots and heart problems after hip fracture surgery

Tests rivaroxaban with aspirin after hip fracture surgery in people with heart muscle injury.

Key facts

Who runs it
McMaster University
Where
Canada and Italy3 sites in 2 countriesChoose a country to see its sites
Trial code
Registry title
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
Status
Not yet recruiting
Phase
Phase 3
People taking part
100 people, planned
Started
1 Dec 2025
Expected to end
1 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • rivaroxaban and ASA
  • Low-molecular weight heparin
  • Fondaparinux
  • Direct Oral Anticoagulant (DOAC)
Record updated
14 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 45 or older who had surgery for a hip fracture from a minor fall or similar low-energy injury. They must also show heart muscle injury, seen as a raised troponin blood test.

Age
45 years and older
Sex
All sexes
Disease stage
Had surgery for a hip fracture caused by a low-energy injury, with heart muscle injury afterwards.
Earlier treatment
People already taking rivaroxaban 2.5 mg twice daily plus ASA before the fracture cannot join.
Biomarker or test result
Raised troponin level in the blood, a sign of heart muscle injury.

Main reasons for not taking part

  • Kidney filtration rate (GFR) below 15mL/min, or serious liver disease (Child-Pugh B or C)
  • Allergy to the study drugs, a bleeding problem, or another need for blood thinners or dual antiplatelet drugs
  • Taking drugs that strongly affect P-gp or CYP3A4, such as ketoconazole or ritonavir
  • Pregnancy, breast-feeding, or able to get pregnant without using birth control or abstinence
  • Major surgery expected within 90 days, or taking part in another blood thinner or antiplatelet study

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age ≥45 years, received surgery for a hip fracture due to a low-energy mechanism, and myocardial injury (i.e., an elevated troponin measurement)

Who cannot take part

  • Centers in which standard of care for VTE prophylaxis after hip fractures is ASA, alone or in combination with other drugs; patients with GFR <15mL/min; patients with drug interactions and conditions that prevent the use of the standard of care or intervention [Known allergy to the study drugs; pregnancy; an indication for anticoagulation, for dual antiplatelet therapy, for a P2Y12 inhibitor; already on rivaroxaban 2.5 mg twice daily + ASA before the fracture; bleeding diathesis that in the judgment of the investigator precludes the use of anticoagulant prophylaxis; history of significant hepatic disease (Child-Pugh B or C, see supplementary material) or any other condition that, in the judgment of the investigator, precludes the use of rivaroxaban; concomitant use of drugs that are strong inhibitors or strong inducers of P-glycoprotein (P-gp, e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus [HIV]-protease inhibitors, such as ritonavir) and/or Cytochrome P450 3A4 (CYP3A4)]; expected requirement for major surgery post-arthroplasty within 90 days; women Persons of childbearing potential who are not abstinent or do not use appropriate contraception or are breast-feeding; unable or unwilling to provide consent; previous participation in the HIPSTER trial; participation in another anticoagulant or antiplatelet study

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.

The 2 groups in the trial

  • rivaroxaban plus ASAExisting treatment, for comparison

    rivaroxaban 2.5mg twice daily plus ASA 75-100mg daily for 90 days

    Treatment: rivaroxaban and ASA

  • standard VTE prophylaxis with an anticoagulantExisting treatment, for comparison

    Institution's standard of care for thromboprophylaxis with a low-dose anticoagulant for \~30 days (as per the standard of care). Regimens could include low-molecular-weight heparin, fondaparinux, or direct oral anticoagulant.

    Treatment: Low-molecular weight heparin, Fondaparinux, and Direct Oral Anticoagulant (DOAC)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial
Plain-language title
Rivaroxaban plus aspirin to prevent blood clots and heart problems after hip fracture surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
14 November 2025